| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14656566.2017.1414182 |
| P698 | PubMed publication ID | 29212383 |
| P2093 | author name string | Chiara Benedetto | |
| G Allais | |||
| Giulia Chiarle | |||
| Silvia Sinigaglia | |||
| P2860 | cites work | A review of frovatriptan for the treatment of menstrual migraine | Q27025002 |
| CGRP may play a causative role in migraine | Q28216666 | ||
| Calcitonin gene-related peptide: physiology and pathophysiology | Q28249298 | ||
| Vasoactive peptide release in the extracerebral circulation of humans during migraine headache | Q28265001 | ||
| The International Classification of Headache Disorders, 3rd edition (beta version) | Q29392338 | ||
| Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data | Q30740922 | ||
| Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies | Q31119065 | ||
| Treatment of menstrual migraine; multidisciplinary or mono-disciplinary approach | Q33571052 | ||
| Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium | Q33571681 | ||
| Menstrual Migraine in A Representative Dutch Population Sample: Prevalence, Disability and Treatment | Q34192963 | ||
| Prevalence of migraine on each day of the natural menstrual cycle | Q34336315 | ||
| Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. | Q34341673 | ||
| Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study | Q34597128 | ||
| A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine | Q34657719 | ||
| Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial | Q34664152 | ||
| Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study | Q34673690 | ||
| Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan | Q34890784 | ||
| Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. | Q35522772 | ||
| Burden of migraine related to menses: results from the AMPP study | Q35528985 | ||
| Oestrogen and attacks of migraine with and without aura | Q35781144 | ||
| Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies | Q35996147 | ||
| Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study | Q36052155 | ||
| Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review | Q36260321 | ||
| Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan | Q36261320 | ||
| Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine | Q36332493 | ||
| Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis--part 2. | Q36450684 | ||
| Triptans in prevention of menstrual migraine: a systematic review with meta-analysis | Q36749560 | ||
| Menstrual migraine: a clinical review | Q36771978 | ||
| Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies. | Q36865920 | ||
| Menstrual migraine: a review of hormonal causes, prophylaxis and treatment | Q36904875 | ||
| Menstrual migraine: clinical and therapeutical aspects | Q36941893 | ||
| Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles | Q37063446 | ||
| Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones | Q37217617 | ||
| Epidemiology and biology of menstrual migraine | Q37348696 | ||
| CGRP and its receptors provide new insights into migraine pathophysiology | Q37785745 | ||
| Treatment of perimenstrual migraine with triptans: an update | Q38014363 | ||
| The impact of extended-cycle vaginal ring contraception on migraine aura: a retrospective case series | Q38025745 | ||
| Treatment of menstrual migraine: utility of control of related mood disturbances | Q38202138 | ||
| COX inhibitors for the treatment of migraine | Q38227997 | ||
| New strategies for the treatment and prevention of primary headache disorders. | Q38992306 | ||
| CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. | Q39193269 | ||
| Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study | Q39250004 | ||
| Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. | Q39277602 | ||
| Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study | Q39284852 | ||
| Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials | Q39301902 | ||
| Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. | Q39320854 | ||
| Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines | Q39324446 | ||
| Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. | Q39324667 | ||
| Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies | Q39336473 | ||
| Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. | Q39351455 | ||
| Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients | Q39356663 | ||
| Efficacy of oral naratriptan in the treatment of menstrually related migraine | Q39361381 | ||
| Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies | Q39439173 | ||
| Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group | Q39452008 | ||
| Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients | Q39464740 | ||
| The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group | Q39470308 | ||
| Treatment of menstrual migraine | Q41718933 | ||
| Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. | Q41741495 | ||
| Thalamic sensitization transforms localized pain into widespread allodynia | Q42441340 | ||
| Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium | Q42622418 | ||
| Perimenstrual migraines and their response to preventive therapy with topiramate | Q42669098 | ||
| Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea | Q43114700 | ||
| Perimenstrual eletriptan prevents menstrual migraine: an open-label study | Q43126264 | ||
| Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks | Q43265529 | ||
| Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation | Q43277042 | ||
| Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. | Q43551354 | ||
| Migraine prevalence, disease burden, and the need for preventive therapy | Q43983035 | ||
| Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine | Q44132929 | ||
| Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study | Q44751658 | ||
| Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial | Q44751669 | ||
| Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine | Q44849382 | ||
| Phyto-oestrogens in the prophylaxis of menstrual migraine | Q44931475 | ||
| A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine | Q44995793 | ||
| Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine | Q45179690 | ||
| Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study | Q45482939 | ||
| Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers | Q46051440 | ||
| Naratriptan in the short-term prophylaxis of pure menstrual migraine. | Q46519066 | ||
| Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration | Q46967136 | ||
| Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine | Q47703173 | ||
| Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system | Q47747629 | ||
| Improvement of migraine with change from combined hormonal contraceptives to progestin-only contraception with desogestrel: How strong is the effect of taking women off combined contraceptives? | Q47877751 | ||
| Deficiency of female sex hormones augments PGE2 and CGRP levels within midbrain periaqueductal gray | Q48572184 | ||
| The neurobiology of vascular head pain | Q48641194 | ||
| A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. | Q50801832 | ||
| Combined oral contraceptives in women with menstrual migraine without aura. | Q51015226 | ||
| Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. | Q51229352 | ||
| Serotonin in trigeminal ganglia of female rodents: relevance to menstrual migraine. | Q51788432 | ||
| Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. | Q51933475 | ||
| Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). | Q52884717 | ||
| Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. | Q53159141 | ||
| Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. | Q54041700 | ||
| A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. | Q54130765 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | menstruation | Q12171 |
| pharmacotherapy | Q701216 | ||
| P304 | page(s) | 123-136 | |
| P577 | publication date | 2017-12-07 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Menstrual migraine: a review of current and developing pharmacotherapies for women | |
| P478 | volume | 19 |
Search more.